Febrile neutropenia

What it is

Febrile neutropenia is fever with a very low neutrophil count, often an absolute neutrophil count (ANC) below 500 cells/mm3, and is a medical emergency. In adults, it is commonly defined as a single oral temperature of 38.3°C (101°F) or higher, or 38.0°C (100.4°F) or higher sustained for more than 1 hour, together with severe neutropenia. It most often happens after chemotherapy, especially with regimens that suppress the bone marrow, and it can also occur with blood cancers, stem cell transplant, or some targeted and immunosuppressive treatments.

The key point is urgency: in a neutropenic patient, fever may be the only sign of a serious infection, and broad-spectrum antibiotics are usually started immediately, often before the exact source is known. Many patients do not have the usual redness, pus, or strong inflammatory symptoms because neutrophils are too low to mount a normal response.

A simple way to think about it is:

Feature	Typical definition
Fever	Single oral temperature at least 38.3°C, or at least 38.0°C for more than 1 hour
Neutropenia	ANC below 500 cells/mm3, or expected to fall below 500 soon
Why it matters	High risk of bacterial or fungal infection and sepsis

In India, patients receiving chemotherapy are often told to report fever immediately and not wait for the next clinic day. That advice is important because delays in assessment and antibiotics can worsen outcomes.

How it works

Neutrophils are white blood cells that help the body control bacteria and fungi. Chemotherapy can damage rapidly dividing cells in the bone marrow, which lowers neutrophil production for several days after treatment. During this period, even ordinary bacteria from the skin, mouth, gut, or hospital environment can cause infection.

Fever may occur because of:

1. A documented infection, such as bloodstream infection, pneumonia, urinary infection, or infection around a central venous catheter.
2. An infection that is present but not easily found on initial tests.
3. Less commonly, noninfectious causes such as the cancer itself, some drugs, blood transfusion reactions, or inflammation.

The risk is highest when neutropenia is both deep and prolonged. Patients with haematologic malignancies, induction chemotherapy, or stem cell transplant often have longer periods of severe neutropenia than patients receiving many standard solid-tumour regimens.

Diagnosis / how it's measured

Diagnosis starts with two things: confirming fever and checking the blood count. The ANC is calculated from the complete blood count and differential. Severe neutropenia usually means ANC below 500 cells/mm3, and some clinicians also consider patients high risk if the ANC is below 1,000 and expected to drop quickly.

Initial evaluation usually includes:

• Complete blood count with differential
• Kidney and liver function tests
• Blood cultures, usually from a vein and from each lumen of a central line if present
• Urine testing if urinary symptoms are present
• Chest imaging if there are respiratory symptoms or low oxygen levels
• Careful exam of the mouth, skin, catheter site, lungs, abdomen, and perianal area

Doctors also assess how sick the patient appears and whether they are low risk or high risk for complications. Risk tools such as the MASCC score or CISNE may be used in selected patients, but they do not replace clinical judgment. A patient with low blood pressure, confusion, breathing difficulty, severe abdominal pain, or signs of sepsis is treated as high risk.

Importantly, a normal-looking exam does not rule out serious infection in neutropenia. Blood cultures may be negative even when infection is present.

Evidence and uses

Febrile neutropenia is treated as an oncologic emergency. The standard approach is prompt empiric broad-spectrum antibiotics that cover likely bacteria, especially gram-negative organisms including Pseudomonas. Treatment is started as soon as possible after cultures are drawn, but antibiotics should not be delayed if cultures are difficult to obtain.

Common management steps include:

Management step	Why it is done
Immediate empiric antibiotics	Reduces risk of sepsis and death
IV fluids and monitoring	Supports blood pressure and organ function
Source evaluation	Looks for line infection, pneumonia, gut infection, urinary infection, and others
Hospital admission for high-risk patients	Allows rapid treatment and monitoring
Growth factor prevention in selected future cycles	Can lower risk in patients with high chemotherapy-related risk

Some lower-risk patients may be treated with oral antibiotics and close follow-up, but only after formal assessment and only if they are clinically stable, can take oral medicines, and have reliable access to urgent care. Many cancer centres prefer admission if there is any doubt.

If fever persists despite antibiotics, clinicians reassess for resistant bacteria, hidden infection sites, viral illness, drug fever, and invasive fungal infection. Empiric antifungal therapy may be considered in selected patients with persistent fever and prolonged neutropenia.

Prevention matters. Guidelines support prophylactic granulocyte colony-stimulating factor, such as filgrastim or pegfilgrastim, when the expected risk of febrile neutropenia from a chemotherapy regimen is high, often 20% or more, or when patient-specific factors increase risk. These factors can include older age, poor nutritional status, prior febrile neutropenia, extensive prior treatment, kidney or liver dysfunction, and advanced disease.

When to see a clinician

Any patient on chemotherapy or with known neutropenia should seek urgent medical care for fever. Do not self-treat at home with only paracetamol and wait to see if it settles.

Get urgent help right away for:

• Temperature 38.3°C once, or 38.0°C lasting more than 1 hour
• Chills or rigors
• New cough, breathlessness, or low oxygen
• Burning urination
• Severe mouth sores or inability to drink
• Abdominal pain, diarrhoea, or vomiting
• Redness, pain, or discharge around a catheter
• Dizziness, low blood pressure, confusion, or extreme weakness

For patients in India, the practical plan should be clear before chemotherapy starts: know which hospital to contact after hours, whether your centre has an emergency oncology pathway, and whether you should come directly to the emergency department if fever develops.

Limitations and open questions

Not every fever in neutropenia is caused by a proven infection, and in many cases no organism is identified. That can make treatment decisions harder, especially when fever persists.

There is ongoing research on the best way to tailor antibiotics, identify low-risk patients safely for outpatient care, and use biomarkers or rapid molecular tests to find infections earlier. Evidence also continues to evolve on when to add antifungal treatment and how to manage patients with resistant organisms.

Definitions are broadly similar across guidelines, but details can vary by centre, patient population, and local resistance patterns. That is especially relevant in hospitals where multidrug-resistant bacteria are common. Because of this, local oncology and infectious disease protocols remain important alongside international guidance.